MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
about
Non-coding landscapes of colorectal cancermicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentmiRNA-124 in Immune System and Immune DisordersThe miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancerTumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and TherapyMicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinomaMiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.miR-155-5p inhibition promotes the transition of bone marrow mesenchymal stem cells to gastric cancer tissue derived MSC-like cells via NF-κB p65 activationmiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.Cancer stem cells as a potential therapeutic target in thyroid carcinoma.MiRNA-based therapeutic intervention of cancer.MicroRNAs and Cancer Drug Resistance.miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Non-coding RNAs Functioning in Colorectal Cancer Stem Cells.MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.Low expression of miR-1469 predicts disease progression and unfavorable post-surgical clinical outcomes in patients with esophageal squamous cell cancer.miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14.In vitro and in vivo effects of miRNA-19b/20a/92a on gastric cancer stem cells and the related mechanism.MicroRNAs and cancer: Key paradigms in molecular therapy.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.
P2860
Q26778014-6A9CB480-C815-4B3F-BD72-C4A8094C7A5CQ26778918-631B9B10-7686-4D2E-AB33-765A2F3E4BCFQ28071632-569B2F40-0386-4CCE-B35F-EBEC86858E73Q28468629-5293DC2F-2250-4961-A2DF-1440F524E2BAQ28817133-EA3872FD-B64E-4C0F-B217-B7DEE060DF62Q36081114-325BC17C-8A0E-492B-8FF7-367EDE1FEB7EQ36214179-7E4B6CB7-DBB5-4CBE-9D5E-654E3763F784Q37086079-DDD7FB73-4A4E-4A4C-8A83-61082DBF864AQ37236236-B68D7B72-84BF-4C60-90A0-A4C79C8CDC1EQ37288044-10E4D513-F251-43BB-A772-4C22DD029982Q38524274-090EC697-1D2D-4E5B-9D46-C38544501D4EQ38748118-EA98E988-3AC6-429B-A9CD-CD36B3BFA668Q38812266-8056A195-926A-45C1-89CD-350264C62F7EQ38826542-D6FD532A-8D9F-4DF3-9E1B-A4F61104F1DBQ38940597-98190EEE-B193-448B-8F92-B4E04F4FDA4AQ39990148-96465187-7FD5-4753-BA82-A043DC8B3882Q40509393-4E8B475C-6524-4A12-833A-FC7B37DF29FAQ41980198-763A622D-5CE7-4E86-9704-559585EBC371Q47121115-41EEB6EF-A16D-4F48-8C72-103FE2E9036BQ49321970-1D6389DA-AB43-455F-9559-488ED96FF172Q49424922-D550A578-7E45-4F8D-9353-2694698796A2Q52726721-5F708BF1-6177-4B82-8399-6448E2EC920E
P2860
MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
@en
type
label
MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
@en
prefLabel
MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
@en
P2860
P1476
MicroRNAs: master regulators of drug resistance, stemness, and metastasis
@en
P2093
Jitao David Zhang
Ozgür Sahin
P2860
P2888
P304
P356
10.1007/S00109-014-1129-2
P50
P577
2014-02-09T00:00:00Z
P5875
P6179
1002816175